TriSalus director buys 361,098 common shares

TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock.

Rhea-AI Filing Summary

TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock. He bought 243,900 shares directly at $4.10 per share and 117,198 shares at $4.10 per share through Skyview Investments LLC.

After these transactions, his direct holdings total 787,132 common shares, and his indirect holdings through Skyview Investments LLC total 199,698 common shares, reflecting continued equity ownership aligned with the company’s shareholders.

Insider Trade Summary

Net Buyer: 361,098 shares

Net Buy 2 txns

Insider Stansky Michael P

Role Director

Bought 361,098 shs ($1.48M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	243,900	$4.10	$1000K
Purchase	Common Stock	117,198	$4.10	$481K

Holdings After Transaction: Common Stock — 787,132 shares (Direct); Common Stock — 199,698 shares (Indirect, By LLC)

Footnotes (1)

1. F1. These securities were purchased by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TriSalus Life Sciences (TLSI) report for Michael P. Stansky?

Michael P. Stansky reported buying additional TriSalus Life Sciences common shares in open-market transactions. He purchased 243,900 shares directly and 117,198 shares indirectly, both at $4.10 per share, increasing his total direct and indirect ownership positions in the company.

How many TriSalus (TLSI) shares did Michael P. Stansky buy and at what price?

Michael P. Stansky bought 243,900 TriSalus common shares directly and 117,198 shares indirectly. All these purchases were executed at a price of $4.10 per share, as part of reported open-market transactions in the company’s common stock.

What are Michael P. Stansky’s total direct and indirect holdings in TriSalus (TLSI) after the Form 4?

After the reported transactions, Michael P. Stansky directly owns 787,132 TriSalus common shares. Indirectly, through Skyview Investments LLC, he holds 199,698 common shares, reflecting the updated ownership balances disclosed in the Form 4 filing for these purchases.

How were some of Michael P. Stansky’s TriSalus (TLSI) shares purchased indirectly?

A portion of the purchased TriSalus shares was acquired by Skyview Investments LLC. Michael P. Stansky serves as managing member of Skyview Investments LLC and, in that capacity, exercises voting and dispositive power over the securities held by the LLC entity.

Were the TriSalus (TLSI) insider transactions by Michael P. Stansky buys or sales?

The reported TriSalus insider transactions by Michael P. Stansky were purchases, not sales. Both entries are coded as open-market purchases of common stock, increasing his direct and indirect ownership positions rather than reducing or disposing of existing shareholdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stansky Michael P

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		P		243,900	A	$4.1	787,132	D
Common Stock	02/23/2026		P		117,198	A	$4.1	199,698	I	By LLC(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities were purchased by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.